Previsioni

Il prezzo obiettivo medio degli analisti è 1158,53 € (+17,46%). La mediana è 1179,72 € (+19,61%).

Acquista	33
Mantieni	9
Vendi	3

Notizie Vai al feed delle notizie

JPMorgan raises price target for Eli Lilly and sees over $100 billion opportunity in obesity market

JPMorgan affirms an overweight rating for Eli Lilly, raises the price target to $1,400 and materially increases revenue and earnings estimates for 2027. The bank expects incretin drugs to generate more than $62 billion in 2026 and exceed $100 billion by 2030, and forecasts total revenue growth to about $135 billion by 2030. Eli Lilly has gained market share versus Novo Nordisk in the U.S. obesity and diabetes markets, though legal disputes and risks remain, including competitive pressure, price regulation and potential pipeline setbacks. » Altro su finanzen.net
Eli Lilly highlighted among seven Wolfe Research growth stocks

Wolfe Research identifies seven growth stocks that posted Q2 revenue and earnings beats, are expected to deliver at least 15% revenue growth in 2026, and have positive price momentum. The list includes Caterpillar, Amphenol, EMCOR Group, Fortinet, Zebra Technologies, Eli Lilly and Incyte, with Zebra and Eli Lilly standing out for their comparatively lower valuations. Eli Lilly is seen as particularly attractive: analysts expect about 20% annual revenue growth through 2028 (to roughly $113.7 billion) driven by GLP‑1 products and oncology, about 30% annual EPS growth, while its relative valuation has come down. » Altro su finanzen.net
Eli Lilly leads valuation rally and carries high valuation premium

Eli Lilly is growing rapidly: Q2 revenue rose 48% to $23 billion, driven by Mounjaro and Zepbound, and revenue guidance was raised. However, the strong performance has created a high valuation premium, leaving little room for disappointment. By comparison, Pfizer and Merck look cheap due to patent and restructuring questions, while Moderna is speculative, driven by promising cancer data. » Altro su finanzen.net

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2026, Eli Lilly & Co ha già distribuito 2,99 € di dividendi. L'ultimo pagamento è avvenuto a giugno.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Eli Lilly & Co ha registrato ricavi pari a 20,13 Mld € e un utile netto di 6,22 Mld €

(EUR)	giugno 2026	YoY
Ricavi	20,13 Mld	52,51%
Utile lordo	17,27 Mld	55,24%
Utile netto	6,22 Mld	29,45%
EBITDA	8,1 Mld	27,27%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	931,12 Mld €
Numero di azioni	941,74 Mln
Massimo/minimo a 52 settimane	1113,11 € - 613,15 €
Rendimento da dividendo	0,56%
Dividendi TTM	5,55 €
Prossimo dividendo	1,49 €
Beta	0,50
Rapporto P/E	38,47
Rapporto PEG	0,41
Rapporto P/B	30,24
Rapporto P/S	13,57

Profilo aziendale

Eli Lilly and Company erforscht, entwickelt und vermarktet weltweit Humanarzneimittel. Es bietet Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, Insulin Lispro, Insulin Lispro Protamin, Insulin Lispro Mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R und Humulin U-500 für Diabetes; und Jardiance, Trajenta und Trulicity für Typ-2-Diabetes. Das Unternehmen bietet Alimta für nicht-kleinzelligen Lungenkrebs (NSCLC) und bösartiges Pleuramesotheliom; Cyramza für metastasierenden Magenkrebs, Adenokarzinom des gastroösophagealen Übergangs, metastasierenden NSCLC, metastasierenden kolorektalen Krebs und hepatozelluläres Karzinom; Erbitux für kolorektale Karzinome und verschiedene Kopf- und Halskrebsarten; Retevmo für metastasierten NSCLC, medullären Schilddrüsenkrebs und Schilddrüsenkrebs; Tyvyt für rezidivierte oder refraktäre klassische Hodgkin-Lymphome und nicht-squamösen NSCLC; und Verzenio für HR+, HER2- metastasierten Brustkrebs, knotenpositiven und frühen Brustkrebs. Es bietet Olumiant für rheumatoide Arthritis und Taltz für Plaque-Psoriasis, psoriatische Arthritis, ankylosierende Spondylitis und nicht-radiographische axiale Spondylarthritis. Das Unternehmen bietet Cymbalta für depressive Störungen, diabetische periphere neuropathische Schmerzen, generalisierte Angststörungen, Fibromyalgie und chronische Muskel-Skelett-Schmerzen; Emgality für Migräne-Prävention und episodische Cluster-Kopfschmerzen; und Zyprexa für Schizophrenie, bipolare Störung und bipolare Erhaltung. Seine Bamlanivimab und Etesevimab und Bebtelovimab für COVID-19; Cialis für erektile Dysfunktion und benigne Prostatahyperplasie; und Forteo für Osteoporose. Das Unternehmen arbeitet mit der Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AbCellera Biologics Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc. und Foghorn Therapeutics Inc. zusammen. Eli Lilly and Company wurde 1876 gegründet und hat seinen Hauptsitz in Indianapolis, Indiana.

Nome	Eli Lilly & Co
CEO	David A. Ricks
Sede centrale	Indianapolis, in Stati Uniti
Sito web	lilly.com
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	01/06/1972
Dipendenti	50.000